secwatch.observer — SEC 8-K summary
======================================

Issuer:     20/20 Biolabs, Inc. (AIDX)
CIK:        0001139685
Form:       8-K
Filed at:   2026-04-01T23:59:59+00:00
Accession:  0001213900-26-037770
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

20/20 BioLabs FY 2025 revenue $2.0M (+17%); gross margin expands; $5M private placement
--------------------------------------------------------------------------------

- Revenue $2.0M (+17% YoY); gross profit $0.6M (+68%); gross margin 29.6% vs 20.6%.
- Operating expenses down 35% to $3.9M; net loss improved 33% to ($3.7)M; cash $1.0M.
- Completed $5.0M private placement Feb 2026; up to $40M available in tranches.
- MDH awarded $520K to 18 fire departments for OneTest MCED; Medicare MCED pathway law signed Feb 2026.
- Launched OneTest for Longevity with IBM AI; exclusive license with ROKIT Healthcare for CKD prediction.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1139685/000121390026037770/0001213900-26-037770-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1139685/000121390026037770/ea028443201-8k_2020bio.htm
  HTML page:      https://secwatch.observer/filing/0001213900-26-037770

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer